ClinicalTrials.gg
CompletedNCT00048776Updated Jul 19, 2005

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

A Phase 4 interventional study of Pletal in Raynaud's Disease, sponsored by Otsuka America Pharmaceutical. Completed at 19 sites in United States. Open to participants aged 5 Years to 16 Years. Per ClinicalTrials.gov, last updated 2005-07-19.

Sponsored by Otsuka America Pharmaceutical (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
5 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Raynaud Disease with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Raynaud Disease · United States.

Enrollment
11th of 33
75 · median 34
Started
2001
with 2 others
Phase 4
5 of 33
1 open now
Registered
1st of 33
by date
Lead sponsor
2 of 33
Otsuka America Pharmaceutical

Among the 33 studies in Raynaud Disease with a site in United States, this one is the 11th largest by enrollment, is one of 3 that started in 2001, is one of 5 in phase 4, and was the 1st registered.

Raynaud Disease

81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.

Browse Raynaud Disease studies →

Open to participants now

2 of the 33 studies in Raynaud Disease with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Raynaud Disease studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 5 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Raynaud Disease with a site in United States, or all of them as a file.
02

Study summary

Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed connective tissue disease. When children with secondary Raynaud's are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of secondary Raynaud's episodes in juvenile patients.

03

Conditions studied

  • Raynaud's Disease

Keywords

  • Secondary Raynaud's
  • circulatory
  • vascular
  • scleroderma
  • lupus
  • mixed connective tissue disease
04

Who can participate

Ages eligible
5 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • 5 to 16 years old
  • fulfill diagnostic criteria for primary or secondary Raynaud's
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
75 participants

Interventions

06

Study locations

19 sites
  • Advanced Medical Clinical Therapeutics
    Anchorage, Alaska 99508, United States
  • Advanced Medical Research Institute
    Fresno, California 93710, United States
  • Madera Family Medical Group
    Madera, California 93637, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • LaRabida Children's Hospital
    Chicago, Illinois 60649, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • St. Louis University Health Sciences Center
    St. Louis, Missouri 63104, United States
  • Children's Hospital
    Omaha, Nebraska 68114, United States
  • Asthma & Allergy Research Center
    Newark, New Jersey 07103, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Children's Hospital of Buffalo
    Buffalo, New York 14222, United States
  • Schneider Children's Hospital
    New Hyde Park, New York 11040, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Jobst Vascular Center
    Toledo, Ohio 43606, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • The Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Monarch Research Associates
    Norfolk, Virginia 23510, United States
  • Children's Hospital and Regional Medical Center
    Seattle, Washington 98105, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2002
First posted
Nov 11, 2002
Start
Oct 2001
Completion
Jun 2003
Last update
Jul 19, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 19, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00048776
First posted
Nov 11, 2002
Start date
Oct 2001
Completion
Jun 2003
Last update
Jul 19, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion